Herlev Hospital

Running trials

• Not yet recruiting

  Sarcoma and Intra-infusion Exercise for Better Outcomes

  NCT07785882· Kira Bloomquist· Source

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· University of Aarhus· Source

• Recruiting

  Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

  NCT07694414· Phase 1· Inge Marie Svane· Source

• Recruiting

  A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

  2026-525417-31-00· Phase 2· Ribocure Pharmaceuticals AB· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors

  NCT07860398· Optheras AS· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· OncoZenge AB· Source

• Recruiting

  Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

  NCT07501117· Phase 1· Inge Marie Svane· Source

• Recruiting

  Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma

  2025-524953-15-00· Phase 1· Region Hovedstaden· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy

  NCT07466212· Odense University Hospital· Source

• Recruiting

  Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

  NCT06892210· Phase 4· Copenhagen Respiratory Research· Source

• Not yet recruiting

  Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

  NCT07409844· Phase 2· Ismail Gögenur· Source

• Recruiting

  Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders

  NCT07824102· Martin Blomberg Jensen· Source

• Recruiting

  The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations

  NCT07312981· University of Copenhagen· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

  NCT07215182· Phase 2· Barbara Malene Fischer· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Recruiting

  Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

  2023-506400-99-00· Phase 2· Vall D Hebron Institute Of Oncology· Source

• Recruiting

  T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

  NCT06783270· Phase 1· Inge Marie Svane· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  NCT06534983· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Continuous Glucose Monitoring in Dialysis Patients With Diabetes

  NCT06641765· Bo Feldt-Rasmussen· Source

• Recruiting

  Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

  NCT06166654· Phase 3· Johannes Grand· Source

• Recruiting

  ADP-TILIL7

  2023-509665-20-00· Phase 1· Herlev Hospital· Source

• Active, not recruiting

  A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.

  2023-507684-19-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Integrated Approach in Frail Older People with Atrial Fibrillation

  NCT06775028· Heart Care Foundation· Source

• Recruiting

  Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

  NCT05056220· Phase 3· Aleksander Krag· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Recruiting

  DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure

  NCT05276219· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  Rescue of Nephrons With ALE.F02 (RENAL-F02)

  NCT06047171· Phase 2· Alentis Therapeutics AG· Source

• Recruiting

  Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial

  2022-502633-26-00· Phase 3· Aarhus University Hospital· Source

• Recruiting

  GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

  NCT06111105· Claus Lindbjerg Andersen· Source

• Recruiting

  DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

  NCT06076811· University of Aarhus· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

  NCT05933577· Phase 3· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

  NCT05707949· Phase 3· AbbVie· Source

• Recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

  NCT05711394· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications

  2022-501006-34-01· Phase 3· Odense University Hospital· Source

• Active, not recruiting

  IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer

  NCT06040632· University of Aarhus· Source

• Recruiting

  Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions

  NCT04945174· Herlev Hospital· Source

• Enrolling by invitation

  Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes

  NCT05368220· University of Copenhagen· Source

Showing 50 of 79.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma9 recruiting
• Heart failure5 recruiting
• Chronic kidney disease4 recruiting
• Colorectal cancer4 recruiting
• Atrial fibrillation3 recruiting
• Bladder cancer3 recruiting
• Lung cancer3 recruiting
• Prostate cancer3 recruiting
• Sarcoma3 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• COPD2 recruiting
• Crohn's disease2 recruiting
• Migraine2 recruiting
• Peripheral artery disease2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Gestational diabetes1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Hyperparathyroidism1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  ARIISE - ASCs in recently diagnosed non-ischemic heart failure

  NCT06840275· Phase 2· Cell2Cure ApS· Source

• Completed

  Patient- and Family-centred Care in the Adult Intensive Care Unit: a Feasibility Study

  NCT06974214· Herlev Hospital· Source

• Active, not recruiting

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Orismilast for the treatment of moderate to severe ulcerative colitis

  2022-502763-37-02· Phase 2· Hvidovre Hospital· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

  2022-502787-20-00· Phase 2· IO Biotech ApS· Source

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

  NCT05615220· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

  NCT05223491· Jørgen Bjerggaard Jensen· Source

• Completed

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· Phase 2· Amgen Inc.· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

  2023-506310-43-00· Phase 1· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Bristol Myers Squibb International Corporation· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  AI Augmented Training for Skin Specialists

  NCT04758988· Herlev Hospital· Source

• Completed

  The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

  NCT05084235· Phase 2· Jacob Moller· Source

• Completed

  The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

  NCT05042973· Phase 2· Jacob Moller· Source

• Completed

  HOLT-ED: Holter-monitoring in End-stage Renal Disease

  NCT04876963· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  Quantitative ICG Fluorescence Angiography in Colorectal Surgery

  NCT05153954· Zealand University Hospital· Source

• Completed

  Cardiac Arrhythmia in Patients With End-Stage Renal Disease

  NCT04841304· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  When to INDuce for OverWeight? (WINDOW)

  NCT04603859· University of Aarhus· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC

  NCT04191096· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

  NCT03740126· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

  NCT03708328· Phase 1· Hoffmann-La Roche· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  Quality of Life the Danish Multiple Myeloma Patients

  NCT02892383· Odense University Hospital· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Pfizer· Source

• Completed

  Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

  NCT02231749· Phase 3· Bristol-Myers Squibb· Source

• Completed

  An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

  NCT01968109· Phase 1/2· Bristol-Myers Squibb· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· AbbVie· Source

• Completed

  Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism

  NCT01611896· Copenhagen University Hospital, Rigshospitalet· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma57 works · 18 trials
• Hidradenitis suppurativa9 works · 0 trials
• Graves' disease and hyperthyroidism5 works · 1 trial
• Tourette syndrome5 works · 2 trials
• Familial hypercholesterolaemia4 works · 0 trials